MedPath

Effects of Cherry Consumption on Metabolic Health

Not Applicable
Completed
Conditions
Metabolic Health
Registration Number
NCT07155915
Lead Sponsor
Instituto Politécnico da Guarda
Brief Summary

This study is designed to evaluate the effects of daily sweet cherry consumption on markers of metabolic health in adults. Cherries are rich in bioactive compounds, such as anthocyanins and phenolic acids, which may help reduce oxidative stress, inflammation, and early risk factors for conditions like type 2 diabetes and cardiovascular disease. Participants will consume 280 grams of fresh sweet cherries every day for 42 consecutive days. Blood and urine samples will be collected at four time points: before the intervention (baseline), at day 21, at day 42 (end of the intervention), and two weeks after stopping cherry consumption.

The study will measure changes in blood sugar regulation, markers of inflammation, oxidative stress, liver and kidney function, and immune response. Waist circumference and body mass index will also be recorded.

The aim of this study is to test whether daily cherry consumption can support metabolic health in healthy adults and to provide data that may inform larger and longer clinical trials in the future.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • Age 18-65 years old
  • Healthy individuals with no known metaboli disorders
Exclusion Criteria
  • Alcohol consumption
  • Smoking
  • Adverse or allergic reaction to cherries
  • Use of antibiotics, anxiolytics, or dietary supplements
  • Pregnancy or lactation
  • Weight changes greater than 10% in the previous year.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Changes in fasting glucoseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in HbA1cBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in insulinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in estimated average glucoseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in IL-6Baseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in gluthatione reductaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in AGP-1Baseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in C-reactive proteinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in gluthatione peroxidaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in glutamate dehydrogenaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Secondary Outcome Measures
NameTimeMethod
Changes in LDL cholesterolBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in aspartate aminotransferaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in alanine transaminaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in gamma-glutamyl transferaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in total bilirubinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in conjugated bilirubinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in unconjugated bilirubinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in lactate dehydrogenaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in total proteinsBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in albuminBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in microalbuminBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in ureaBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in creatinineBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in TIBCBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in transferrinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in uric acidBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in ironBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in ferritinBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in amylaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in lipaseBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in IgABaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in IgGBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in HDL cholesterolBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in IgMBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in total IgEBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in rheumatoid factorBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in antistreptolysin OBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in triglyceridesBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in total cholesterolBaseline, Day 21, Day 42 and 2 weeks post-intervention
Changes in waist circumferenceBaseline and Day 42
Body Mass IndexBaseline and Day 42

Trial Locations

Locations (1)

Instituto Politécnico da Guarda

🇵🇹

Guarda, Portugal

Instituto Politécnico da Guarda
🇵🇹Guarda, Portugal

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.